The Motley Fool··Adria CiminoVertex Pharmaceuticals Diversifies Beyond Cystic Fibrosis With Gene-Editing Expansion
Vertex Pharmaceuticals expands beyond cystic fibrosis dominance into gene-editing treatments for blood disorders and pain management, targeting $13.1B revenue with non-CF products generating $500M+.
VRTXbiotechpharmaceutical innovation